Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Chen N, Bellone CJ, Schriewer J, Owens G, Fredrickson T, Parker S, Buller RM.

Virology. 2011 Jan 20;409(2):328-37. doi: 10.1016/j.virol.2010.10.021. Epub 2010 Nov 10.

2.

The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.

Robbins SJ, Jackson RJ, Fenner F, Beaton S, Medveczky J, Ramshaw IA, Ramsay AJ.

Antiviral Res. 2005 Apr;66(1):1-7. Epub 2005 Jan 25.

PMID:
15781125
3.

A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.

Israely T, Paran N, Lustig S, Erez N, Politi B, Shafferman A, Melamed S.

Virol J. 2012 Jun 18;9:119. doi: 10.1186/1743-422X-9-119.

4.

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.

Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier ER, Painter G, Schriewer J, Trost LC, Buller RM.

Antiviral Res. 2014 Nov;111:42-52. doi: 10.1016/j.antiviral.2014.08.003. Epub 2014 Aug 13.

PMID:
25128688
5.

Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.

Parker S, Chen NG, Foster S, Hartzler H, Hembrador E, Hruby D, Jordan R, Lanier R, Painter G, Painter W, Sagartz JE, Schriewer J, Mark Buller R.

Antiviral Res. 2012 Apr;94(1):44-53. doi: 10.1016/j.antiviral.2012.02.005. Epub 2012 Feb 18.

6.

Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.

Parker S, Schriewer J, Oberle C, Robertson A, Lanier R, Painter G, Buller RM.

Antivir Ther. 2008;13(7):863-73.

7.

Ectromelia virus: the causative agent of mousepox.

Esteban DJ, Buller RM.

J Gen Virol. 2005 Oct;86(Pt 10):2645-59. Review.

PMID:
16186218
8.

Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.

Crump R, Korom M, Buller RM, Parker S.

Antiviral Res. 2017 Mar;139:112-116. doi: 10.1016/j.antiviral.2016.12.015. Epub 2016 Dec 27.

PMID:
28039021
9.

A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.

Alejo A, Saraiva M, Ruiz-Argüello MB, Viejo-Borbolla A, de Marco MF, Salguero FJ, Alcami A.

PLoS One. 2009;4(4):e5175. doi: 10.1371/journal.pone.0005175. Epub 2009 Apr 13.

10.

Deficiency in Th2 cytokine responses exacerbate orthopoxvirus infection.

Sakala IG, Chaudhri G, Eldi P, Buller RM, Karupiah G.

PLoS One. 2015 Mar 9;10(3):e0118685. doi: 10.1371/journal.pone.0118685. eCollection 2015.

11.
12.

Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.

Parker S, Siddiqui AM, Oberle C, Hembrador E, Lanier R, Painter G, Robertson A, Buller RM.

Virology. 2009 Mar 1;385(1):11-21. doi: 10.1016/j.virol.2008.11.015. Epub 2008 Dec 18.

13.

Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.

Parker S, Touchette E, Oberle C, Almond M, Robertson A, Trost LC, Lampert B, Painter G, Buller RM.

Antiviral Res. 2008 Jan;77(1):39-49. Epub 2007 Sep 4.

PMID:
17904231
14.

The Pathogenesis and Immunobiology of Mousepox.

Sigal LJ.

Adv Immunol. 2016;129:251-76. doi: 10.1016/bs.ai.2015.10.001. Epub 2015 Nov 21. Review.

PMID:
26791861
15.

Redundant Function of Plasmacytoid and Conventional Dendritic Cells Is Required To Survive a Natural Virus Infection.

Kaminsky LW, Sei JJ, Parekh NJ, Davies ML, Reider IE, Krouse TE, Norbury CC.

J Virol. 2015 Oct;89(19):9974-85. doi: 10.1128/JVI.01024-15. Epub 2015 Jul 22.

16.

Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.

Quenelle DC, Prichard MN, Keith KA, Hruby DE, Jordan R, Painter GR, Robertson A, Kern ER.

Antimicrob Agents Chemother. 2007 Nov;51(11):4118-24. Epub 2007 Aug 27.

17.

The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses.

Melo-Silva CR, Tscharke DC, Lobigs M, Koskinen A, Wong YC, Buller RM, Müllbacher A, Regner M.

J Virol. 2011 Nov;85(21):11170-82. doi: 10.1128/JVI.00256-11. Epub 2011 Aug 17.

18.

T cell cytokine synthesis at the single-cell level in BALB/c and C57BL/6 mice infected with ectromelia virus.

Szulc L, Gieryńska M, Winnicka A, Martyniszyn L, Boratyńska-Jasińska A, Niemiałtowski M.

Postepy Hig Med Dosw (Online). 2012 Apr 20;66:222-30.

19.

Comparable polyfunctionality of ectromelia virus- and vaccinia virus-specific murine T cells despite markedly different in vivo replication and pathogenicity.

Hersperger AR, Siciliano NA, Eisenlohr LC.

J Virol. 2012 Jul;86(13):7298-309. doi: 10.1128/JVI.00038-12. Epub 2012 Apr 24.

20.

Innate Immune Gene Transcript Level Associated with the Infection of Macrophages with Ectromelia Virus in Two Different Mouse Strains.

Dolega P, Szulc-Dąbrowska L, Bossowska M, Mielcarska M, Nowak Z, Toka FN.

Viral Immunol. 2017 Jun;30(5):315-329. doi: 10.1089/vim.2016.0173. Epub 2017 Apr 28.

PMID:
28453414

Supplemental Content

Support Center